Inside J&J’s strategy to de-gender clinical trials

“Men with prostate cancer” is a common phrase in clinical trial protocols for prostate cancer treatments. But for pharma and biotech companies that want to move the needle on improving clinical trial diversity and including more LGBTQ+ people in their research, a problem has emerged with these phrases.